CureVac is expecting good news in its patent infringement cases for components of its Covid-19 vaccine against Pfizer partner BioNTech in Germany after a court postponed proceedings on four cases, the company announced Thursday.
CureVac said that courts in Germany only suspend proceedings if they believe there has been infringement on patented property.
“Given the particularities of German patent law, where patent infringement and validity are adjudicated by separate proceedings, the suspension of proceedings until the validity of intellectual property rights has been determined was expected,” CureVac CEO Alexander Zehnder said in a statement.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.